Loading
A health centre in Tamuning, Guam, that since 2019 has let patients on Guam join United States National Cancer Institute trials locally.
The University of Guam reported in 2019 that the National Cancer Institute had approved, in January, the addition of FHP Health Center, Guam, to its Community Oncology Research Program (NCORP) through the University of Hawai'i Cancer Center's Minority/Underserved NCORP, allowing patients in Guam to take part in NCI-sponsored cancer clinical trials, which the Cancer Research Center of Guam would facilitate. The site's principal investigator, Dr Samir Ambrale, said 95 per cent of cancer care is delivered locally in Guam. ClinicalTrials.gov lists "FHP Health Center-Guam" in Tamuning as a site for NCI-MATCH, ALCHEMIST, DART (S1609) and other cooperative group trials. OnCo could not reach FHP's own site. The coordinates are an approximate Tamuning city point.
Shares DART (SWOG S1609): nivolumab plus ipilimumab in rare tumours, ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials), NCI-MATCH (EAY131).
Shares Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer, BWEL (Breast Cancer Weight Loss, Alliance A011401), ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials).
Shares Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors, DART (SWOG S1609): nivolumab plus ipilimumab in rare tumours, ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/